Figure 8. Potency of Foxp3+ Tregs expanded by both OX86 and IL-2/mAb complex in vivo.
(A). Naïve foxp3gfp reporter mice were treated with OX86, IL-2/Ab complex or both. The treated mice were sacrificed 8 days later, and CD4+GFP(Foxp3)+ Tregs in the spleen and lymph nodes were sorted. The sorted Tregs (1×105/well) were mixed with CFSE labeled responder T cells, and the cell mixture was stimulated by anti-CD3/APCs. T cell proliferation, as defined by CFSE dilutions, was assessed by FACS. The plot presented is 1 of 3 individual experiments. (B). Comparison of lung pathology in mice treated with OX86 and OX86 plus IL-2/Ab complex. H&E staining, 10×. (C). Wt B6 mice were injected with OX86 (0.25 mg i.p. ×3) and IL-2/Ab complex (0.3 ug i.p. ×3) on days -7, -6, -5 and then transplanted with Balb/c heart allografts on day 0. Groups of recipients were also given a single i.p. injection of MR1 (0.25 mg i.p.) at the time of transplantation, and transplant survival was shown in a Kaplan-Meir plot.